SCHEMBL3338658

SCHEMBL3338658

O=C(NNc1nc(-c2ccc(Br)cc2)cs1)c1ccncc1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.71
KDM4E B2RXH2 11/20 0.71
GAA P10253 11/20 0.71
ALDH1A1 P00352 8/20 0.71
MEN1 O00255 7/20 0.71
KMT2A Q03164 7/20 0.71
HTT P42858 6/20 0.71
SMN1; SMN2 Q16637 5/20 0.71
LMNA P02545 6/20 0.64
RAB9A P51151 3/20 0.63
TDP1 Q9NUW8 3/20 0.61
MAPK1 P28482 3/20 0.61
PARP1 P09874 1/20 0.58
NPSR1 Q6W5P4 1/20 0.54
CA12 O43570 1/20 0.53
CA9 Q16790 1/20 0.53
ROCK1 Q13464 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C19 P33261 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3339116 0.88 MAPT (0.64) MAPTKDM4EGAAALDH1A1MEN1
SCHEMBL3338134 0.87 KDM4E (0.85) MAPTKDM4EGAAALDH1A1MEN1
SCHEMBL3341958 0.86 MAPT (0.79) MAPTKDM4EGAAALDH1A1MEN1
SCHEMBL3343782 0.86 MAPT (0.78) MAPTKDM4EGAAALDH1A1MEN1
SCHEMBL3339779 0.86 LMNA (0.79) MAPTKDM4EGAAALDH1A1MEN1
SCHEMBL3340440 0.84 MAPT (0.61) MAPTKDM4EGAAALDH1A1MEN1
SCHEMBL3344076 0.81 MAPT (0.66) MAPTKDM4EGAAALDH1A1MEN1
SCHEMBL3341776 0.79 MAPT (0.89) MAPTKDM4EGAAALDH1A1MEN1
SCHEMBL12249044 0.78 PARP1 (0.78) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL3341872 0.78 MAPT (0.61) MAPTKDM4EGAAALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US claimed
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 US disclosed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA MAPT 2/4885KDM4E 4489/4885GAA 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.